{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:39:35Z","timestamp":1774535975577,"version":"3.50.1"},"reference-count":8,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Case Reports"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Due to SARS\u2010COV\u20102 (COVID\u201019) pandemic and its catastrophic impact on society, the FDA granted emergency use authorization for some vaccines. Possible rare side effects could not have been observed in this relatively short period. We are reporting an elderly lady with multiple comorbidities who presented with progressive lower limb weakness that started seven days after receiving the first dose of the COVID\u201019 vaccine. The electrodiagnostic study showed demyelinating polyneuropathy with secondary axonal degeneration consistent with Guillain\u2013Barr\u00e9 syndrome. We ruled out other possible causes for GBS, suggesting a postvaccine nature for her presentation. The patient received intravenous immunoglobulin (IVIG) for five days and gradually improved, which supports our initial diagnosis.<\/jats:p>","DOI":"10.1002\/ccr3.5237","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T15:03:25Z","timestamp":1642518205000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Could Guillain\u2013Barr\u00e9 syndrome be triggered by COVID\u201019 vaccination?"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2748-6990","authenticated-orcid":false,"given":"Maya","family":"Aldeeb","sequence":"first","affiliation":[{"name":"Department of Medical Education Hamad Medical Corporation Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7184-1235","authenticated-orcid":false,"given":"Lina","family":"Okar","sequence":"additional","affiliation":[{"name":"Department of Medical Education Hamad Medical Corporation Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safa S.","family":"Mahmud","sequence":"additional","affiliation":[{"name":"Department of Medical Education Hamad Medical Corporation Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gholam A.","family":"Adeli","sequence":"additional","affiliation":[{"name":"Department of Neurology Movement Disorder and Neurophysiology Hamad Medical Corporation Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Food and Drug Administration.Research C for BE and Development and Licensure of Vaccines to Prevent COVID\u201019. U.S. Published October 23 2020. Accessed February 13 2021.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/development\u2010and\u2010licensure\u2010vaccines\u2010prevent\u2010covid\u201019"},{"key":"e_1_2_11_3_1","unstructured":"FDA.Research C for BE and Emergency Use Authorization for Vaccines Explained. Published online December 14 2020. Accessed February 13 2021.https:\/\/www.fda.gov\/vaccines\u2010blood\u2010biologics\/vaccines\/emergency\u2010use\u2010authorization\u2010vaccines\u2010explained"},{"key":"e_1_2_11_4_1","unstructured":"FDA.Commissioner O of the. Pfizer\u2010BioNTech COVID\u201019 Vaccine. Published online February 3 2021. Accessed February 12 2021.https:\/\/www.fda.gov\/emergency\u2010preparedness\u2010and\u2010response\/coronavirus\u2010disease\u20102019\u2010covid\u201019\/pfizer\u2010biontech\u2010covid\u201019\u2010vaccine"},{"key":"e_1_2_11_5_1","unstructured":"CDC.Guillain\u2010Barr\u00e9 syndrome and Flu Vaccine. Published April 19 2019. Accessed February 13 2021.https:\/\/www.cdc.gov\/flu\/prevent\/guillainbarre.htm"},{"key":"e_1_2_11_6_1","unstructured":"WHO Director\u2010General\u2019s opening remarks at the media briefing on COVID\u201019 \u2010 11 March 2020. Accessed February 13 2021.https:\/\/www.who.int\/director\u2010general\/speeches\/detail\/who\u2010director\u2010general\u2010s\u2010opening\u2010remarks\u2010at\u2010the\u2010media\u2010briefing\u2010on\u2010covid\u201019\u2010\u2010\u201011\u2010march\u20102020"},{"key":"e_1_2_11_7_1","doi-asserted-by":"crossref","unstructured":"NEJM.Safety and Efficacy of the BNT162b2 mRNA Covid\u201019 Vaccine. Accessed February 12 2021. doi:10.1056\/NEJMoa2034577","DOI":"10.1056\/NEJMoa2034577"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102506"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010020\u201010124\u2010x"}],"container-title":["Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.5237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ccr3.5237","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.5237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T10:27:15Z","timestamp":1693218435000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccr3.5237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1002\/ccr3.5237"],"URL":"https:\/\/doi.org\/10.1002\/ccr3.5237","archive":["Portico"],"relation":{},"ISSN":["2050-0904","2050-0904"],"issn-type":[{"value":"2050-0904","type":"print"},{"value":"2050-0904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2021-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e05237"}}